Search
zuranolone (Zurzuvae)
Indications:
- postpartum depression (FDA_approved)
Dosage:
- 30-50 mg PO QD
Pharmacokinetics:
- rapidly-acting antidepressant, benefit within 2 weeks
Adverse effects:
- generally well tolerate
- somnolence, headache, sedation, dizziness
Mechanism of action:
- analogue of a neuroactive progesterone metabolite with effects GABA brain circuits
Interactions
drug adverse effects of antidepressants
General
antidepressant
Database Correlations
PUBCHEM cid=86294073
References
- Deligiannidis KM et al.
Zuranolone for the treatment of postpartum depression.
Am J Psychiatry 2023 Jul 26; [e-pub].
PMID: 37491938
https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.20220785
- Deligiannidis KM et al.
Effect of zuranolone vs placebo in postpartum depression:
A randomized clinical trial.
JAMA Psychiatry 2021 Sep 1; 78:951.
PMID: 34190962 PMCID: PMC8246337 Free PMC article
https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2781385